GLP-1, exendin-4, peptide analogs and uses thereof

US8853160B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Nigel H. Greig · Phoenix, US
• Josephine Egan · Baltimore, US
• Maire Doyle · Baltimore, US
• Harold W. Holloway · Middle River, US
• Tracy Ann Perry · Baltimore, US

Key dates

• Filing date: Aug 24, 2012
• Grant date: Oct 7, 2014
• Expiry date: Aug 24, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/26
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel polypeptide analogs of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogs thereof for neuroprotective and neurotrophic effects.